-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Misunderstandings About Cancer DNA TestsMany cancer patients who received genomic testing of their cancers in a clinical trial did not fully understand the purpose of the testing.
by Emma Yasinski
-
A Researcher Attends a Conference, This Time as a Patient AdvocateMy most meaningful moments at my first cancer research conference came from embracing my experience as a patient—not as a researcher.
by Jamie Aten
-
PARP Inhibitors in Pancreatic CancerDrugs that target DNA repair enzymes may provide alternatives to long-term chemotherapy for some patients with pancreatic cancer.
by Kate Yandell
-
Telling Their Stories Through PostersSurvivors and advocates display their posters alongside the work of thousands of cancer researchers.
by Kevin McLaughlin
-
The Crowded Field of Checkpoint InhibitorsDrug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
Drug Costs and Cancer CareExperts discuss the value of cancer treatments in a climate of rising drug prices.
by Kevin McLaughlin
-
What Is Hyper-Progression?Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
Risk Reduction, Clinical Trials Are Focus of Atlanta Community EventCancer researchers, patient advocates and community members gathered for a public forum presented by the American Association for Cancer Research.
by Kevin McLaughlin
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
by Sandra Gordon
Lessons From 20 Years Living With CancerMultiple myeloma survivor Jonathan Gluck reflects on uncertainty, and the scientific progress that has kept him living with cancer for more than two decades.
by Eric Fitzsimmons
The Enduring Importance of Cancer Disparities ResearchOpening session from AACR conference highlights how perseverance and adversity have informed cancer disparities research over the years.
by Eric Fitzsimmons
Most Cancer Survivors Don’t Meet Healthy Diet GoalsDespite research linking fruits and vegetables to cancer survival, many people do not change their eating habits after diagnosis.
by Darlene Dobkowski
-
Keeping Hope Alive—Why the Schlueters Rally for Medical ResearchRichard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
-
Cancer in the Rearview Mirror: 15 Years of AACR Cancer Progress Report Survivor StoriesCancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
Cancer Research at a Crossroads
